drugset / Trial / NCT02429089

Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck

NCT02429089

NaSingle-groupOpen-labelTreatment

Summary

In this trial, the investigators would like to investigate the activity of LEE011 associated with cetuximab (standard of care for the SCCHN patients at this stade of the disease).

Timeline

Start
2015-04
Primary completion
2017-09-01
Completion
2018-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule 400 mg Oral
Subject Ribociclib Small molecule 600 mg Oral